Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, Dahr S, Sran P, Reed GF, Robinson R, Ragheb JA, Waldmann TA, Nussenblatt RB.

J Autoimmun. 2008 Sep;31(2):91-7. doi: 10.1016/j.jaut.2008.05.001. Epub 2008 Jun 20.

2.

Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.

Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, Buggage RR.

Ophthalmology. 2005 May;112(5):764-70.

PMID:
15878055
3.

High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.

Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, Ryan JG, Hammel K, Nussenblatt RB.

Am J Ophthalmol. 2009 Nov;148(5):696-703.e1. doi: 10.1016/j.ajo.2009.06.003. Epub 2009 Aug 6.

4.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR.

J Autoimmun. 2003 Nov;21(3):283-93. Erratum in: J Autoimmun. 2004 Aug;23(1):93.

PMID:
14599854
5.

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.

Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ.

Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):63-70.

6.

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group.

Ophthalmology. 2015 May;122(5):939-48. doi: 10.1016/j.ophtha.2014.12.033. Epub 2015 Jan 29.

PMID:
25638011
7.

Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.

Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, Hanout M, Hassan M, Afridi R, Agarwal A, Halim MS, Do DV, Nguyen QD.

Am J Ophthalmol. 2017 Nov;183:71-80. doi: 10.1016/j.ajo.2017.08.019. Epub 2017 Sep 5.

PMID:
28887113
8.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

9.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
10.

[Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].

Hernández Garfella ML, Díaz Llopis M, Salom Alonso D, Cervera Taulet E.

Arch Soc Esp Oftalmol. 2004 Dec;79(12):593-8. Spanish.

PMID:
15627927
11.

Daclizumab for treatment of birdshot chorioretinopathy.

Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS.

Arch Ophthalmol. 2008 Feb;126(2):186-91. doi: 10.1001/archophthalmol.2007.49.

PMID:
18268208
12.

Intravenous daclizumab for recalcitrant ocular inflammatory disease.

Bhat P, Castañeda-Cervantes RA, Doctor PP, Foster CS.

Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):687-92. doi: 10.1007/s00417-009-1043-4. Epub 2009 Feb 6.

PMID:
19198869
13.

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, Sran P, Yaffe A, Goldman CK, Waldmann TA, Whitcup SM.

Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7462-6.

14.

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF.

Ophthalmology. 2012 Aug;119(8):1575-81. doi: 10.1016/j.ophtha.2012.02.018. Epub 2012 Apr 21.

PMID:
22525047
15.

Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.

Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P.

Ophthalmology. 2000 Nov;107(11):2024-33.

PMID:
11054326
16.

Biological response modifier therapy for refractory childhood uveitis.

Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS.

Br J Ophthalmol. 2007 Oct;91(10):1341-4. Epub 2007 Jun 7.

17.

Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.

Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM, El Mollayess G, Mansour AM.

Ocul Immunol Inflamm. 2016 Jun;24(3):319-26. doi: 10.3109/09273948.2014.990041. Epub 2014 Dec 30.

PMID:
25549063
18.

Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.

Markomichelakis N, Delicha E, Masselos S, Sfikakis PP.

Am J Ophthalmol. 2012 Sep;154(3):534-541.e1. doi: 10.1016/j.ajo.2012.03.035. Epub 2012 Jul 11.

PMID:
22789563
19.

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT.

Arch Ophthalmol. 2005 Jul;123(7):903-12.

PMID:
16009830
20.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.

Gut. 2006 Nov;55(11):1568-74. Epub 2006 Apr 7.

Supplemental Content

Support Center